Age-Dependent Effects of A53T Alpha-Synuclein on Behavior and Dopaminergic Function

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Oaks, Adam W ^a   Frankfurt, Maya ^b   Finkelstein, David I ^c   Sidhu, Anita ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; DOPAMINE; DOPAMINE TRANSPORTER; GAMMA SYNUCLEIN; TAU PROTEIN;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CELL COUNT; CONTROLLED STUDY; DEPRESSION; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVATION; MOTOR PERFORMANCE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SUBSTANTIA NIGRA PARS COMPACTA; TAUOPATHY;

AGE FACTORS; ALPHA-SYNUCLEIN; ANIMALS; BETA-SYNUCLEIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-SYNUCLEIN; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PRIONS; PROMOTER REGIONS, GENETIC; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TAU PROTEINS;

ANIMALIA; MUS;

EID: 84875638056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060378     Document Type: Article

References (74)

1. Chaudhuri KR, Healy DG, Schapira AH, (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245.
2. Chaudhuri KR, Schapira AH, (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8: 464-474.
3. Dawson TM, Ko HS, Dawson VL, (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646-661.
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
5. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, et al. (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68: 568-578.
6. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, et al. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24: 419-429.
7. Lee MK, Stirling W, Xu Y, Xu X, Qui D, et al. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-->Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99: 8968-8973.
8. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533.
9. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20: 6021-6029.
10. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20: 6365-6373.
11. Emmer KL, Waxman EA, Covy JP, Giasson BI, (2011) E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem 286: 35104-35118.
12. Ikeda M, Kawarabayashi T, Harigaya Y, Sasaki A, Yamada S, et al. (2009) Motor impairment and aberrant production of neurochemicals in human [alpha]-synuclein A30P+A53T transgenic mice with [alpha]-synuclein pathology. Brain Research 1250: 232-241.
13. Oaks AW, Sidhu A, (2011) Synuclein modulation of monoamine transporters. FEBS Lett 585: 1001-1006.
14. Elhwuegi AS, (2004) Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 28: 435-451.
15. Taylor TN, Greene JG, Miller GW, (2010) Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 211: 1-10.
16. McDowell K, Chesselet MF, (2012) Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 46: 597-606.
17. George S, van den Buuse M, San Mok S, Masters CL, Li QX, et al. (2008) Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 210: 788-792.
18. Unger EL, Eve DJ, Perez XA, Reichenbach DK, Xu Y, et al. (2006) Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis 21: 431-443.
19. Graham DR, Sidhu A, (2010) Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res 88: 1777-1783.
20. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23: 183-189; quiz 313.
21. Jeannotte AM, McCarthy JG, Redei EE, Sidhu A, (2009) Desipramine modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an animal model of depression. Neuropsychopharmacology 34: 987-998.
22. Wersinger C, Prou D, Vernier P, Niznik HB, Sidhu A, (2003) Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol Cell Neurosci 24: 91-105.
23. Wersinger C, Jeannotte A, Sidhu A, (2006) Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein. Eur J Neurosci 24: 3141-3152.
24. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, et al. (2011) Tauopathic changes in the striatum of A53T alpha-synuclein mutant mouse model of Parkinson's disease. PLoS One 6: e17953.
25. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, et al. (2011) Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci 33: 1598-1610.
26. Kaul T, Credle J, Haggerty T, Oaks AW, Masliah E, et al. (2011) Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci 12: 79.
27. Wills J, Credle J, Oaks AW, Duka V, Lee JH, et al. (2012) Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS One 7: e30745.
28. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, et al. (2005) Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol 192: 274-287.
29. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
30. Yao I, Takao K, Miyakawa T, Ito S, Setou M, (2011) Synaptic E3 Ligase SCRAPPER in Contextual Fear Conditioning: Extensive Behavioral Phenotyping of Scrapper Heterozygote and Overexpressing Mutant Mice. PLoS One 6: e17317.
31. Martins-Silva C, De Jaeger X, Guzman MS, Lima RD, Santos MS, et al. (2011) Novel strains of mice deficient for the vesicular acetylcholine transporter: insights on transcriptional regulation and control of locomotor behavior. PLoS One 6: e17611.
32. Sango K, McDonald MP, Crawley JN, Mack ML, Tifft CJ, et al. (1996) Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat Genet 14: 348-352.
33. Jeannotte AM, Sidhu A, (2007) Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules. Eur J Neurosci 26: 1509-1520.
34. Zhou W, Freed CR, (2004) Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem 279: 10128-10135.
35. Blackstone CD, Moss SJ, Martin LJ, Levey AI, Price DL, et al. (1992) Biochemical characterization and localization of a non-N-methyl-D-aspartate glutamate receptor in rat brain. J Neurochem 58: 1118-1126.
36. Lau LF, Mammen A, Ehlers MD, Kindler S, Chung WJ, et al. (1996) Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102. J Biol Chem 271: 21622-21628.
37. Adams JC, (1981) Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem 29: 775.
38. Parish CL, Finkelstein DI, Drago J, Borrelli E, Horne MK, (2001) The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci 21: 5147-5157.
39. Hung LW, Villemagne VL, Cheng L, Sherratt NA, Ayton S, et al. (2012) The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med 209: 837-854.
40. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, et al. (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18: 291-295.
41. Frankfurt M, Salas-Ramirez K, Friedman E, Luine V, (2011) Cocaine alters dendritic spine density in cortical and subcortical brain regions of the postpartum and virgin female rat. Synapse 65: 955-961.
42. George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, et al. (2010) alpha-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced alpha-synuclein and PINK1 levels after rotenone treatment. J Mol Neurosci 42: 243-254.
43. Sotiriou E, Vassilatis DK, Vila M, Stefanis L (2009) Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiol Aging.
44. Yavich L, Jakala P, Tanila H, (2006) Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J Neurochem 99: 724-732.
45. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, et al. (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28: 425-433.
46. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, et al. (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62: 218-229.
47. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, et al. (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 20: 2302-2312.
48. Duka T, Sidhu A, (2006) The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-Synuclein, in SH-SY5Y neuroblastoma cells. Neurotox Res 10: 1-10.
49. Duka T, Duka V, Joyce JN, Sidhu A (2009) {alpha}-Synuclein contributes to GSK-3{beta}-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J.
50. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, et al. (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 225: 210-218.
51. Lindvall O, Bjorklund A, (1978) Anatomy of the dopaminergic neuron systems in the rat brain. Adv Biochem Psychopharmacol 19: 1-23.
52. Yoshida H, Hastie CJ, McLauchlan H, Cohen P, Goedert M, (2004) Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J Neurochem 90: 352-358.
53. Wersinger C, Vernier P, Sidhu A, (2004) Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant. Biochemistry 43: 1242-1253.
54. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, et al. (2007) Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 170: 658-666.
55. Lee FJ, Liu F, Pristupa ZB, Niznik HB, (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15: 916-926.
56. Wersinger C, Sidhu A, (2005) Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 44: 13612-13624.
57. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22: 8797-8807.
58. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 99: 14524-14529.
59. Pena-Oliver Y, Buchman VL, Stephens DN, (2010) Lack of involvement of alpha-synuclein on unconditioned anxiety in mice. Behav Brain Res 209: 234-240.
60. Kuhn M, Haebig K, Bonin M, Ninkina N, Buchman VL, et al. (2007) Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics 8: 71-81.
61. Salahpour A, Ramsey AJ, Medvedev IO, Kile B, Sotnikova TD, et al. (2008) Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci U S A 105: 4405-4410.
62. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, et al. (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 5: e11464.
63. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26: 11915-11922.
64. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
65. Platt NJ, Gispert S, Auburger G, Cragg SJ, (2012) Striatal dopamine transmission is subtly modified in human A53Talpha-synuclein overexpressing mice. PLoS One 7: e36397.
66. Lindgren HS, Dunnett SB, (2012) Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models? Eur J Neurosci 35: 1894-1907.
67. Fahn S, (2008) The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23 (Suppl 3):: S497-508.
68. Tozzi A, Costa C, Siliquini S, Tantucci M, Picconi B, et al. (2012) Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol Aging 33: 1792-1799.
69. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, et al. (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29: 8103-8113.
70. Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, et al. (2005) Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging 26: 25-35.
71. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, et al. (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26: 41-50.
72. Villalba RM, Smith Y, (2010) Striatal spine plasticity in Parkinson's disease. Front Neuroanat 4: 133.
73. Day M, Wang Z, Ding J, An X, Ingham CA, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259.
74. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, et al. (2010) Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 42: 1775-1778.